Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EP395 in Healthy Adults with Induced Lung Inflammation
NCT05516316Phase 1Completed
- Sponsor
- EpiEndo Pharmaceuticals
- Start
- Oct 2022
- Primary completion
- Jun 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of glasmacinal in chronic obstructive pulmonary disease (COPD) (3 arms), sponsored by EpiEndo Pharmaceuticals. Primary endpoint: Bronchoalveolar lavage fluid interleukin 8 at Day 21. Started Oct 2022; status: completed.
02
Drugs
glasmacinal
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on NCT05516316.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05516316.